Los Angeles, CA, January 8, 2013 -- Perion Network Ltd (NASDAQ: PERI) jumped up 22.65% to $11.61 on a traded volume of 264k shares after the Company provided the guidance for fourth quarter and fiscal year 2013. The Company expects revenues in the fourth quarter of 2012 to reach a record $21 million. This will bring total non-GAAP revenues for 2012 to $61 million. The Company expects revenue to exceed $110 million for 2013. EBITDA is expected to be at least $26 million for 2013. Non-GAAP net income is expected to be at least $20 million for the year 2013.
Will PERI Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://beststocksdaily.com/p2/index.php?company=PERI
Star Scientific Inc (NASDAQ: STSI) increased 9.86% to $3.02. The Company announced successful results from the Company's ASAP Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid. The study was conducted at nine sites and builds upon previous epidemiological and animal experimental studies.
How Should Investors Trade STSI After The Recent Momentum, Find Out Here http://beststocksdaily.com/p2/index.php?company=STSI
Cell Therapeutics Inc (NASDAQ: CTIC) moved up 8.46% to $1.41 on a traded volume of 160k shares. The 52-week range for the stock is $1.14 and $8.25. The 50-Day Moving Average and 200-Day Moving Average prices is $1.32 and $2.02 respectively.
Get Free Special Trend Analysis On CTIC Here http://beststocksdaily.com/p2/index.php?company=CTIC
Peregrine Pharmaceuticals (NASDAQ: PPHM) escalated 11.93% to $2.71 on a traded volume of 984k shares. The Company said flaws in a study of its experimental lung cancer drug bavituximab didn’t extend to the highest treatment dose. An internal review found that discrepancies in a mid-stage study were limited to the placebo and low-dose treatments.
Get Free Special Trend Analysis On PPHM Here http://beststocksdaily.com/p2/index.php?company=PPHM
Venaxis Inc (NASDAQ: APPY) decreased 5.52% to $2.57. The Company has fulfilled the requirements for CE Marking in Europe for APPY1. APPY1 is the Company’s blood-based appendicitis test. The initial commercialization in Europe is planned to start in the first quarter 2013 in key territories, including the UK, Italy, France, Germany and Benelux countries. The Company expects to announce agreements with top EU distributors beginning in the first quarter 2013.
Get Free Special Trend Analysis On APPY Here http://beststocksdaily.com/p2/index.php?company=APPY
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA